103 related articles for article (PubMed ID: 35413730)
41. Scattering of primary care: doctor switching and utilization of health care by children on fee-for-service Medicaid.
Joffe GP; Rodewald LE; Herbert T; Barth R; Szilagyi PG
J Urban Health; 1999 Sep; 76(3):322-34. PubMed ID: 12607899
[TBL] [Abstract][Full Text] [Related]
42. A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
Garcia C; Yao A; Camacho F; Balkrishnan R; Cantrell LA
Gynecol Oncol; 2017 Aug; 146(2):346-350. PubMed ID: 28499649
[TBL] [Abstract][Full Text] [Related]
43. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
44. Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
Ko EM; Bekelman JE; Hicks-Courant K; Brensinger CM; Kanter GP
Gynecol Oncol; 2022 Feb; 164(2):295-303. PubMed ID: 34949437
[TBL] [Abstract][Full Text] [Related]
45. Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
Ha HI; Cho SH; Lim J; Lee YJ; Yoo CW; Won YJ; Lim MC
Gynecol Oncol; 2021 Dec; 163(3):506-510. PubMed ID: 34602286
[TBL] [Abstract][Full Text] [Related]
46. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
47. Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.
Harding BN; Delaney JA; Urban RR; Weiss NS
Gynecol Oncol; 2019 Aug; 154(2):426-431. PubMed ID: 31178150
[TBL] [Abstract][Full Text] [Related]
48. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
Baandrup L
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183052
[TBL] [Abstract][Full Text] [Related]
49. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer.
Fairfield KM; Murray K; LaChance JA; Wierman HR; Earle CC; Trimble EL; Warren JL
Gynecol Oncol; 2014 Sep; 134(3):473-7. PubMed ID: 24952367
[TBL] [Abstract][Full Text] [Related]
50. Cancer outcomes in low-income elders: is there an advantage to being on Medicaid?
Koroukian SM; Bakaki PM; Owusu C; Earle CC; Cooper GS
Medicare Medicaid Res Rev; 2012; 2(2):. PubMed ID: 24800139
[TBL] [Abstract][Full Text] [Related]
51. Gynecologic cancer outcomes in the elderly poor: A population-based study.
Doll KM; Meng K; Basch EM; Gehrig PA; Brewster WR; Meyer AM
Cancer; 2015 Oct; 121(20):3591-9. PubMed ID: 26230631
[TBL] [Abstract][Full Text] [Related]
52. Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.
Knisely A; Huang Y; Melamed A; Tergas AI; St Clair CM; Hou JY; Khoury-Collado F; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2020 Aug; 158(2):415-423. PubMed ID: 32456990
[TBL] [Abstract][Full Text] [Related]
53. Can prenatal care impact future well-child visits? The experience of a low income population in New York State Medicaid managed care.
Cogan LW; Josberger RE; Gesten FC; Roohan PJ
Matern Child Health J; 2012 Jan; 16(1):92-9. PubMed ID: 21127954
[TBL] [Abstract][Full Text] [Related]
54. Changes in ambulatory utilization after switching from Medicaid fee-for-service to managed care.
Kern LM; Rajan M; Pincus HA; Casalino LP; Stuard SS
Am J Manag Care; 2019 Sep; 25(9):e254-e260. PubMed ID: 31518096
[TBL] [Abstract][Full Text] [Related]
55. MMP-16 as a New Biomarker for Predicting Prognosis and Chemosensitivity of Serous Ovarian Cancer: A Study Based on Bioinformatics Analysis.
Wang W; Liu Y; Yang Y; Huang X; Hou Y
Crit Rev Eukaryot Gene Expr; 2021; 31(4):1-8. PubMed ID: 34587431
[TBL] [Abstract][Full Text] [Related]
56. Access denied: The relationship between patient insurance status and access to high-volume hospitals.
Nabi J; Tully KH; Cole AP; Marchese M; Cone EB; Melnitchouk N; Kibel AS; Trinh QD
Cancer; 2021 Feb; 127(4):577-585. PubMed ID: 33084023
[TBL] [Abstract][Full Text] [Related]
57. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
[TBL] [Abstract][Full Text] [Related]
58. Timing of Medicaid Enrollment, Late-Stage Breast Cancer Diagnosis, Treatment Delays, and Mortality.
Xie E; Colditz GA; Lian M; Greever-Rice T; Schmaltz C; Lucht J; Liu Y
JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35583139
[TBL] [Abstract][Full Text] [Related]
59. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer.
Ryerson AB; Eheman C; Burton J; McCall N; Blackman D; Subramanian S; Richardson LC
Obstet Gynecol; 2007 May; 109(5):1053-61. PubMed ID: 17470582
[TBL] [Abstract][Full Text] [Related]
60. The impact of health insurance status on the survival of patients with head and neck cancer.
Kwok J; Langevin SM; Argiris A; Grandis JR; Gooding WE; Taioli E
Cancer; 2010 Jan; 116(2):476-85. PubMed ID: 19937673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
